Clinical Data Novo says high-dose Wegovy can cause 28% weight loss PharmaphorumNovo Nordisk has built the case for migration to its 'triple-dose' version of injectable GLP-1 Wegovy with new weight-loss and body composition data.Metabolic & GLP-1Read full story pharminent May 12, 2026 (Last updated: May 12, 2026) Pharmaphorum Novo Nordisk has built the case for migration to its ‘triple-dose’ version of injectable GLP-1 Wegovy with new weight-loss and body composition data. Metabolic & GLP-1 Read full story Post navigation Previous: A year after Vertex’s big launch, pain drug research faces a pivotal momentNext: FDA turns to old drugs to address new diseases, persistent medical needs Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026